On April 28, 2022 Patrys reported that has published its Quarterly Activities Report and 4C Quarterly Cash Flow Report (Press release, Patrys, APR 28, 2022, View Source [SID1234613121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights for this Quarter have included:

Work on second engineering run of PAT-DX1 expected to complete in current quarter;
Stable cell line for production of PAT-DX3 established;
Receipt of R&D Tax Incentive Refund of $1.2 million.
Our balance sheet closed with a cash balance of $10.16M at 31 March 2022 and an additional $2M in short-term investments.